1. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in onocology. Rectal cancer. Evidence blocks. 2019.
2. Freischlag K, Sun Z, Adam MA, Kim J, Palta M, Czito BG, et al. Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer. JAMA Surg. 2017;152(6):558-64.
3. Sun Z, Adam MA, Kim J, Turner MC, Fisher DA, Choudhury KR, et al. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. Colorectal Dis. 2017;19(12):1058-66.
4. Petrucciani N, Carra MC, Martinez-Perez A, Vitali GC, Landi F, Genova P, et al. Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy. Anticancer Res. 2019;39(4):2113-20.
5. Dossa F, Acuna SA, Rickles AS, Berho M, Wexner SD, Quereshy FA, et al. Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection. JAMA Oncol. 2018;4(7):930-7.
6. Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, et al. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Int J Biol Sci. 2016;12(8):1022-31.
7. Armstrong D, Raissouni S, Price Hiller J, Mercer J, Powell E, MacLean A, et al. Predictors of Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study. Clin Colorectal Cancer. 2015;14(4):291-5.
8. Tseng MSF, Zheng H, Ng IWS, Leong YH, Leong CN, Yong WP, et al. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience. Singapore Med J. 2018;59(6):305-10.
9. Lee SH. How to Achieve a Higher Pathologic Complete Response in Patients With Locally Advanced Rectal Cancer Who Receive Preoperative Chemoradiation Therapy. Ann Coloproctol. 2019;35(1):3-8.
10. Hu H, Huang J, Lan P, Wang L, Huang M, Wang J, et al. CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial. BMC Cancer. 2018;18(1):1145.
11. Kleiman A, Al-Khamis A, Farsi A, Kezouh A, Vuong T, Gordon PH, et al. Normalization of CEA Levels Post-Neoadjuvant Therapy is a Strong Predictor of Pathologic Complete Response in Rectal Cancer. J Gastrointest Surg. 2015;19(6):1106-12.
12. Lee SY, Kim CH, Kim YJ, Kwak HD, Ju JK, Kim HR. Obesity as an independent predictive factor for pathologic complete response after neoadjuvant chemoradiation in rectal cancer. Ann Surg Treat Res. 2019;96(3):116-22.
13. Ren DL, Li J, Yu HC, Peng SY, Lin WD, Wang XL, et al. Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer. World J Gastroenterol. 2019;25(1):118-37.
14. Choi E, Kim JH, Kim OB, Kim MY, Oh YK, Baek SG. Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience. Radiat Oncol J. 2016;34(2):106-12.
15. Chen M, Chen LZ, Xu L, Zhang JS, Song X. Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis. Cancer Manag Res. 2019;11:741-58.
16. Sun Y, Wu X, Zhang Y, Lin H, Lu X, Huang Y, et al. Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. Eur J Surg Oncol. 2019.
17. Gash KJ, Baser O, Kiran RP. Factors associated with degree of tumour response to neo-adjuvant radiotherapy in rectal cancer and subsequent corresponding outcomes. European Journal of Surgical Oncology. 2017;43(11):2052-9.
18. Mace AG, Pai RK, Stocchi L, Kalady M. American Joint Committee on Cancer and College of American Pathologists Regression Grade: A New Prognostic Factor in Rectal Cancer. Dis Colon Rectum. 2015;58:1:32-44.
19. Nitsche U, Friess H, Agha A, Angele M, Eckel R, Heitland W, et al. Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort. J Cancer Res Clin Oncol. 2016;142(11):2357-66.
20. Vallam KC, Desouza A, Bal M, Patil P, Engineer R, Saklani A. Adenocarcinoma of the Rectum-A Composite of Three Different Subtypes With Varying Outcomes? Clin Colorectal Cancer. 2016;15(2):e47-52.
21. Letaief F, Nasri M, Ayadi M, Meddeb K, Mokrani A, Yahyaoui Y, et al. Potential predictive factors for pathologic complete response after the neoadjuvant treatment of rectal adenocarcinoma: a single center experience. Cancer Biol Med. 2017;14(3):327-34.
22. Chan DKH, Tan KK. Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance. J Gastrointest Oncol. 2019;10(1):42-7.
23. Turner MC, Keenan JE, Rushing CN, Gulack BC, Nussbaum DP, Benrashid E, et al. Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. J Gastrointest Surg. 2019.
24. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. JAMA. 2017;318(16):1569-80.
25. Pedziwiatr M, Malczak P, Mizera M, Witowski J, Torbicz G, Major P, et al. There is no difference in outcome between laparoscopic and open surgery for rectal cancer: a systematic review and meta-analysis on short- and long-term oncologic outcomes. Tech Coloproctol. 2017;21(8):595-604.
26. Cleary RK, Morris AM, Chang GJ, Halverson AL. Controversies in Surgical Oncology: Does the Minimally Invasive Approach for Rectal Cancer Provide Equivalent Oncologic Outcomes Compared with the Open Approach? Ann Surg Oncol. 2018;25(12):3587-95.
27. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22-iv40.